<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Mucosal tolerance has been used successfully to treat animal models of <z:hpo ids='HP_0002960'>autoimmune diseases</z:hpo> and is being tested in human diseases </plain></SENT>
<SENT sid="1" pm="."><plain>In this work we demonstrate the reduction of <z:mpath ids='MPATH_124'>infarct</z:mpath> size following mucosal tolerance by myelin oligodendrocyte <z:chebi fb="2" ids="17089">glycoprotein</z:chebi> (MOG) (35-55) <z:chebi fb="7" ids="16670">peptide</z:chebi> in mouse <z:hpo ids='HP_0001297'>stroke</z:hpo> model </plain></SENT>
<SENT sid="2" pm="."><plain>Nasal MOG was most efficacious and reduced ischemic <z:mpath ids='MPATH_124'>infarct</z:mpath> size by 70% at 24 h as well as improving behavior score </plain></SENT>
<SENT sid="3" pm="."><plain>Using immunohistological methods and IL-10 -/- mice, we demonstrate the importance of IL-10-producing CD4+ T cells in the reduction of the ischemic <z:mpath ids='MPATH_124'>infarct</z:mpath> volume following middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) </plain></SENT>
<SENT sid="4" pm="."><plain>Furthermore, adoptive transfer of CD4+ T cells from nasally tolerized mice to untreated mice prior to MCAO surgery significantly decreased <z:hpo ids='HP_0001297'>stroke</z:hpo> size (p&lt;0.001 vs. control), whereas CD4+ T cells from nasally tolerized IL-10-deficient mice had no significant effect </plain></SENT>
<SENT sid="5" pm="."><plain>Based on these results, modulation of cerebral <z:mp ids='MP_0001845'>inflammation</z:mp> by mucosal tolerance to myelin antigens may have applicability both as prophylactic therapy and treatment following <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> attacks </plain></SENT>
</text></document>